|DB01255||Lisdexamfetamine||For the treatment of Attention-deficit/hyperactivity disorder (ADHD) and for moderate to severe binge eating disorder in adults [FDA label], [A40246].
This drug is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss is associated with serious cardiovascular effects. The safety and effectiveness of this drug for the treatment of obesity have not yet been determined [FDA label].
|DB00201||Caffeine||For management of fatigue, orthostatic hypotension, and for the short term treatment of apnea of prematurity in infants.|
|DB00745||Modafinil||To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.|
|DB00182||Amphetamine||Amphetamine is indicated for the treatment of attention-deficit/hyperactivity disorders (ADHD) as well as for the treatment of central nervous system disorders such as narcolepsy.[A18540]
ADHD is a complex disorder associated with the substantial heterogeneity in etiology, clinical presentation, and treatment outcome. ADHD comes from a complex interplay between interdependent genetic and non-genetic factors which cause complex mental disorders in children and teenagers.[A174271]
On the other hand, narcolepsy is a chronic sleep disorder typically resenting during adolescence and characterized by excessive daytime sleepiness.[A174274]
Amphetamine is also being used nowadays off-label for the treatment of obesity, depression and chronic pain.[A174268, A174283]|
|DB01577||Metamfetamine||For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.|
|DB01576||Dextroamphetamine||Used to treat attention deficit hyperactivity disorder (ADHD).|
|DB06701||Dexmethylphenidate||Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment.|
|DB00422||Methylphenidate||For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.|